Drug Combination Details
| General Information of the Combination (ID: C46690) | |||||
|---|---|---|---|---|---|
| Name | Apigenin NP Info | + | TRAIL/Apo2L Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Prostate cancer
[ICD-11: 2C82]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | SLC25A5 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | TRAIL-R2 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | DU145 | CVCL_0105 | Prostate carcinoma | Homo sapiens | ||
| LNCaP | CVCL_0395 | Prostate carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Apigenin sensitizes prostate cancer cells to Apo2L/TRAIL by targeting adenine nucleotide translocase-2. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Apigenin sensitizes prostate cancer cells to Apo2L/TRAIL by targeting adenine nucleotide translocase-2. PLoS One. 2013;8(2):e55922. | |||
